Chantix Success Rate

The Success Rates of Chantix
According to the Chantix website, 44% of the people that used Chantix to help them quit smoking were successful in weeks 9 – 12 of the clinical trials. In two similar studies, 1,022 patients were enrolled and treated with either Chantix, another smoking cessation drug called Zyban, or a sugar pill. 44% of the people treated with Chantix had completely quit smoking during the final weeks of the treatment.

However, according to whyquit.com, that figure “is rather meaningless.”  WhyQuit says “if Chantix is used as a stand-alone quitting aid without ongoing counseling or support, your chances of quitting smoking for one year are probably less than 1 in 11.” WhyQuit also says “Pfizer is failing to adequately alert smokers to the fact that half of varenicline clinical trial users who successfully quit smoking for 12 weeks while using it had relapsed to smoking within a year.”  Pfizer is failing to make known that…”without ongoing counseling and support possibly as few as 9 in 100 users will be smoke-free at 6 months.” http://whyquit.com/pr/082506.html#excluded

According to Drugs.com, Each year about 46% of smokers in the US try to quit, with around 10% of them being successful in the short term (6 – 8 months). To increase your chances of successfully quitting smoking with Chantix, begin the medication 1 week prior to your set quit date for stopping smoking. Increase the medication daily or weekly as your doctor has prescribed, continuing 12 – 24 weeks per your doctor, and get counseling regularly. Outside support of and for your efforts is imperative.

What Effects Chantix Success Rates?
During the initial clinical trials, Pfizer excluded many groups of people from participating in the studies. People that had been diagnosed with major depression, kidney or heart disease, people suffering from alcohol abuse, panic disorders, high blood pressure and many, many other groups of people that have historically been categorized as “the most challenging people to help quit smoking.”  Denial of participation for these groups of people may have caused a higher over all percentage of success rates for Chantix.

It also may have caused Pfizer to not have all the facts on how this medication will affect different types of people, different types of medication reactions, and have higher success rates and percentages overall.

As it turns out, this mistake was a costly one for Pfizer. They are in lawsuits with people all over the country that had been hurt or killed while taking Chantix, or had been hurt themselves, or had a loved one hurt by someone else  taking Chantix.